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A B S T R A C T
We present a unique and informative instance of respiratory syncytial virus (RSV) infection associated
with antiphospholipid syndrome (APS), and discuss this case in the context of the literature addressing
the immunopathogenesis of APS associated with diverse infections. We describe the case of a 43-year-
old man with no signiﬁcant past medical history who presented with the acute onset of fever,
hemoptysis, and extensive bullous, ecchymotic lesions in both lower extremities. Punch biopsy of the
lesion demonstrated thrombotic vasculopathy. Further evaluation revealed serum antiphospholipid
antibodies as well as a positive RSV PCR in a nasal swab specimen. Clinical manifestations, positive
laboratory and pathological ﬁndings were strongly suggestive of APS associated with a recent RSV
infection. When an infectious etiology is considered for APS, RSV should also be included in the
differential diagnosis.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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journal homepage: www.elsevier .com/ locate / idcrWhy this case is important
We present what, to our knowledge, is the ﬁrst reported case of
antiphospholipid syndrome (APS) associated with Respiratory
Syncytial Virus (RSV) infection. APS is a disorder characterized by
vascular thrombosis, or pregnancy-related morbidity, in the
presence of antiphospholipid (aPL) antibodies [1]. APS is classiﬁed
as either primary or secondary, and secondary APS is associated
with autoimmune disease, infection, medication or malignancy
[2]. RSV is a common causative agent of acute viral upper and lower
respiratory tract infection throughout all age groups. Despite the
common occurrence of RSV respiratory infections, an association
or possible causal relationship between RSV and APS has not to our
knowledge been discussed previously. We report a case where
progressive, extensive ecchymoses appeared to be the initial
manifestation of APS occurring in temporal association with, and
seemingly triggered by, a recent episode of RSV infection.* Corresponding author. Present address: Azumabashi 1-23-30, River Pier
Azumabashi Room 2707, Sumida-ku, Tokyo, 130-0001, Japan.
E-mail address: junmakinony@gmail.com (J. Makino).
http://dx.doi.org/10.1016/j.idcr.2016.10.013
2214-2509/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article unCase description
A 43-year-old male with no signiﬁcant past medical history
presented during the month of December with a 4-day history of
fever (maximum temperature 38.8 C), shaking chills, hemoptysis
and worsening dyspnea. He had experienced intermittent night
sweats, pain and swelling of both wrists and ankle joints over the
last several months. He also reported a 10 kg weight loss during
this time, but never sought medical attention. He had noted a
painful ecchymotic lesion on his left calf one day prior to the
admission. Over the subsequent 24 h, the patient developed similar
lesions on his abdomen, back, right upper arm and right calf. The
patient’s 3 year old son had recently had a respiratory illness.
On physical examination, the patient had a temperature of
35.3 C, blood pressure of 117/75 mmHg, pulse rate of 112 beats/
min, respiratory rate of 29 breaths/min, and an oxygen saturation
of 96% on room air. There were bilateral lung wheezes, and
multiple painful ecchymosis with several hemorrhagic bullae over
his trunk and extremities (Fig. 1). CBC on admission showed WBC
9000/mm3 (87% neutrophils) and Hemoglobin 13.4 g/dL, and
comprehensive metabolic panel including electrolytes, liver and
renal function was all within normal range. The signiﬁcant
laboratory data included high lactate dehydrogenase of 799 IU/L,
erythrocyte sedimentation rate of 81 mm/h, and C-reactive protein
level of 38.5 mg/dL. The Xray and computed tomography (CT) of theder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Skin examination on admission a. Right upper arm, b. Right calf.
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pulmonary embolism on a CT angiogram (Fig. 2). Empiric
treatment with intravenous ceftriaxone and oral azithromycin
was initiated for community acquired pneumonia (CAP). The
ecchymoses appeared to worsen on the following day, and the
possibility of an adverse drug reaction was raised. Ceftriaxone and
azithromycin were switched to levoﬂoxacin, and vancomycin was
added. On the second day after admission, a punch biopsy of anFig. 2. CXR and CT of the chest on admission a. CXR, b. CT chest o
Fig. 3. Pathological Findings of punch skin biopsy.
Superﬁcial and deep dermal thrombotic paucicellular vasculitis/vasculopathy involvingecchymotic lesion on the right arm was performed. The
histopathological ﬁndings revealed a superﬁcial and deep dermal
thrombotic paucicellular vasculitis/vasculopathy involving skin
appendages without signiﬁcant neutrophils or leukocytoclasia
(Fig. 3). Tests for cryoglobulin, serum protein electrophoresis
(SPEP), protein C, protein S, b-2 glycoprotein IgM and IgG,
rheumatoid factor, CCP IgG, ds DNA Ab IgG, complement levels,
ANCA, GBM Ab IgG, Scl-70 IgG, SSA,B Ab, Jo-1 IgG Ab were negative.n admission. Both demonstrate bilateral multifocal inﬁltrates.
 adnexa without leukocytoclasia.
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41 s), cardiolipin Ab IgM 64 (normal range: 0–12), and phospha-
tidylserine Ab IgM > 100 (normal range: <10) were positive. A nasal
swab for MRSA and a sputum respiratory culture for bacteria were
negative, and vancomycin was discontinued on the fourth day.
Nasopharyngeal swabs for inﬂuenza antigen, streptococcal anti-
gen, and urine for legionella antigen were negative. Nasal swab for
the FilmArray Respiratory Panel (BioFire) was positive for RSV, but
adenovirus, coronavirus, human metapneumovirus, rhinovirus,
enterovirus, inﬂuenza virus, parainﬂuenza virus, Bordetella
pertussis, chlamydophilia pneumoniae, mycoplasma pneumoniae
were negative. Also, other possible infectious etiologies associated
with APS were investigated, and EBV DNA PCR was positive
(8696 copies/mL), but HIV, CMV, hepatitis A, B and C were negative.
The patient’s respiratory symptoms gradually improved, and a
repeat CT of the chest done on the seventh day post admission
showed interval improvement of the diffuse bibasilar opacities. A
transbronchial lung biopsy performed on day 6 showed intra-
alveolar hemorrhage, interstitial ﬁbrosis and intra-capillary
megakaryocytes. Lung tissue culture grew Actinomyces odontoyi-
ticus and Staphyloccous sacchalolyticus which were considered
contaminants. The patient completed a 7-day course of levoﬂox-
acin with signiﬁcant improvement of his respiratory symptoms.
His skin lesions also gradually improved. The patient improved and
was discharged on hospital day 10, and he has remained in a good
health. It was subsequently found that the patient’s 3-year old son
had been diagnosed with acute RSV infection one week prior to the
patient’s admission. A lupus anticoagulant was again positive 65
(normal range: 27–41 s) 3 months’ after discharge.
Other similar and contrasting cases in the literature
A probable association and a causal relationship between
infections and APS have been well reported, and various organisms
have been implicated [3]. A “two hit” model has been proposed to
explain the pathogenesis of thrombosis of APS [4,5]. Initially,
antiphospholipid (aPL) antibodies bind to endothelial cells and
promote overproduction of tissue factor and thromboxane A2. This
results in a procoagulant state constituting the- “ﬁrst hit”. The
complement cascade is then activated by the aPL antibodies and
the complement system leading to damage of the endothelial cells
and resulting in thrombosis. This process is often potentiated by
the presence of inﬂammation, estrogen or coagulation-regulatory
proteins (protein C, prothrombin, plasmin), -constituting the
“second hit”. When aPL antibodies bind to endothelial cells in
the ﬁrst step, b2-Glycoprotein Inhibitor (b2-GPI) is usually
required as a cofactor to unite aPL antibodies and endothelial
cells. In certain infections, the b2-GPI molecule and the infectious
agents’ epitopes are known to be structurally and sequentially
similar, and this molecular similarity is considered a key
mechanism of APS associated with infection [6]. Hepatitis C virus
(HCV), Epstein-Barr virus (EBV), Varicella virus, Parvovirus B19,
Cytomegalovirus (CMV), Human Immunodeﬁciency virus (HIV),
and Adenovirus are some of the viruses associated with APS and
circulating anti-b2-GPI [7]. In contrast, Sene and coworkers have
suggested that viral infections and some bacterial infections may
be associated with positive anticardiolipin antibodies (aCL), but
not associated with anti b2-GPI as seen in our case [8].
Discussion
The FilmArray Respiratory Panel (BioFire) is a new molecular
test used to assess responses to panel of 20 respiratory viruses and
bacteria [9]. Results are available in several hours and the
sensitivity and speciﬁcity have been reported to be 100% and
89% respectively [9]. In our patient, the test for RSV was positivebut tests for other infectious etiologies previously associated with
APS were negative except for EBV. Although acute EBV infection
has been associated with APS in the previous case reports [10,11],
the lack of cervical lymphadenopathy or hepatosplenomegaly and
a negative anti b2-GPI made acute EBV infection less likely in our
case. In addition, a recent retrospective study found that while the
prevalence of aPLs among patients with acute EBV was 37%, none of
those with aPLs had any symptoms of APS, and the aPLs resolved in
all of those tested [12]. It is plausible however that, within a “two-
hit” model, this patient may have had a condition associated with
aPL antibodies (for instance, EBV or other some other condition
which could have accounted for the patient’s preceding symptoms
of fevers, weight loss, arthralgia, etc.) several months prior to RSV,
and the RSV then served as the inﬂammatory trigger, inducing
symptoms of APS.
The presence of multiple ecchymoses, unexplained intermit-
tent fever, joint swelling and weight loss for several months led to
the consideration of other rheumatologic diseases, such as
rheumatoid arthritis, vasculitis and speciﬁcally systemic lupus
erythematosus (SLE). The American College of Rheumatology
recommends that 4 or more of the 11 proposed criteria are present
to identify patients with SLE [13]. However, our patient did not
meet the diagnostic criteria for any of these diseases and only met
two of the criteria for SLE – a positive immunologic disorder and a
positive antinuclear antibody. Instead, a positive lupus anticoagu-
lant 65 (normal range: 27–41 s) and cardiolipin Ab IgM 18 (normal
range: 0–12) both repeated after 3 months’ of discharge from the
hospital further supported the diagnosis of APS.
In summary, the development of ecchymotic lesions following a
recent respiratory infection, pathologically conﬁrmed thrombotic
vasculopathy in the skin biopsy, a positive aCL IgM, phosphatidyl-
serine Ab IgM and a positive RSV in molecular testing were strongly
suggestive of APS associated with a recent RSV infection (with or
without a prior sensitizing exposure). RSV should also be included in
the differential diagnosis of an infectious etiology for APS.
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